Welcome back to Fast Money. Structure Therapeutic shares doubling today. The stock's best day on record.The biotech out with new data on its once daily GLP1 pill showing patients lost an average 11.3% of their body weight after 36 weeks of treatment. For more, let's bring in Missouo healthcare strategist Jared Holes. Jared, great to have you with us.Um, should Lily be concerned. Should investors in Lily be concerned about this. >> Hey Melissa, I really appreciate it.Um, maybe a little bit. I mean, structure ...

礼来(LLY.N)公司宣布2026年第一季度每股派息1.73美元。 本文源自：金融界AI电报 ...

INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the first quarter of 2026 of $1.73 per share on outstanding common stock. The dividend is payable on March 10, 2026, to shareholders of record at the close of business on February 13, 2026. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and ...

Eli Lilly and Company (NYSE:LLY) is included among the 14 Best US Stocks to Buy for Long Term. Guggenheim Maintains Buy on Eli Lilly (LLY) After “Another Impressive Year” On December 3, Guggenheim raised its price target on Eli Lilly and Company (NYSE:LLY) to $1,163 from $1,036 and kept a Buy rating on the stock. The firm updated its models for LLY based on prescription trends and GLP-1 pricing news. While highlighting that the company “delivered another impressive year of stock performance in 2025,” the ...

Core Viewpoint - Eli Lilly and Company has elected Carolyn R. Bertozzi, Ph.D., as a returning member of its board of directors, effective December 8, 2025, highlighting her significant contributions to targeted medicine development, particularly in oncology [1][2]. Group 1: Board Appointment - Carolyn R. Bertozzi, a Nobel Prize-winning chemist, will serve on the Science and Technology and Ethics and Compliance committees of Lilly's board [1][2]. - David A. Ricks, Lilly's chair and CEO, emphasized the value of Dr. Bertozzi's perspective as the company continues to innovate in oncology and immunology [2]. Group 2: Dr. Bertozzi's Background - Dr. Bertozzi is currently the Baker Family director of Sarafan ChEM-H and a professor at Stanford University, with additional roles in Chemical and Systems Biology and Radiology [2]. - She has received numerous honors and is an elected member of prestigious academies, including the National Academy of Medicine and the National Academy of Sciences [3]. Group 3: Company Overview - Eli Lilly has been a pioneer in medical discoveries for nearly 150 years, focusing on addressing significant health challenges such as diabetes, obesity, Alzheimer's disease, immune system disorders, and difficult-to-treat cancers [4]. - The company is committed to making its medicines accessible and affordable while ensuring diversity in clinical trials [4].

24/7 Wall St. Quick Read Abbott Laboratories (ABT) grew revenue 6.9% with medical devices up 14.8% to $5.45B. Abbott reaffirmed guidance for 7.5-8.0% organic growth. Eli Lilly (LLY) posted 54% revenue growth driven by Mounjaro ($6.52B) and Zepbound ($3.57B). Lilly raised guidance to $63.0-63.5B revenue. Lilly’s operating margin reached 48.3% versus Abbott’s 19.4%. Lilly trades at 49.5x P/E while Abbott trades at 15.71x. If you’re thinking about retiring or know someone who is, there are three quic ...

In terms of sheer relevance, it's difficult to think of a more relevant sector than healthcare — and within this vast ecosystem, only an elite few occupy the same neighborhood as pharmaceutical giant Eli Lilly and Company (NYSE:LLY) . In November 2025, Eli Lilly became the first trillion-dollar pharmaceutical company, mostly due to regulatory momentum for its blockbuster drugs.Specifically, the pharma received approval by the Food and Drug Administration for Mounjaro (tirzepatide) as an adjunct to diet and ...

Core Insights - Abbott Laboratories and Eli Lilly reported fundamentally different Q3 earnings, with Abbott showing steady growth driven by medical devices and Lilly experiencing explosive growth from GLP-1 drugs [1] Abbott Laboratories - Abbott's revenue grew by 6.9% year-over-year, primarily supported by its medical device segment, which increased by 14.8% to $5.45 billion [2] - The cardiovascular portfolio, including TriClip and Navitor TAVI, significantly contributed to growth, while the diagnostics segment saw a decline of 6.6% due to reduced COVID testing revenue [2] - Abbott's operating income rose by 13.1% to $2.06 billion, but net income remained flat year-over-year [2] - The company reaffirmed its outlook for 7.5-8.0% organic growth, excluding COVID testing [3] Eli Lilly - Lilly's revenue surged by 54% year-over-year to $17.60 billion, exceeding estimates by 9.5% [3] - The incretin portfolio, particularly Mounjaro and Zepbound, generated significant revenue, with Mounjaro alone contributing $6.52 billion (up 109%) and Zepbound adding $3.57 billion (up 184%) [3] - Net income for Lilly jumped 475% to $5.58 billion, with an operating margin of 48.3%, nearly double that of Abbott [3] - Lilly raised its full-year revenue guidance to $63.0-63.5 billion and non-GAAP EPS to $23.00-23.70 [3] Business Models - Abbott's diversified business model spreads risk across various segments, including medical devices, diagnostics, nutrition, and branded generics, limiting upside but cushioning downside [5] - In contrast, Lilly's concentrated focus on incretin-based therapies has resulted in over $10 billion in quarterly revenue from Mounjaro and Zepbound, but this concentration also creates vulnerability to market fluctuations [6] Future Outlook - For Abbott, the key focus will be on whether the momentum in cardiovascular devices can offset the decline in diagnostics, with the success of TriClip's Japan launch and Navitor's European expansion being critical [7] - For Lilly, effective supply chain execution is essential to meet demand and maintain its market position, especially as it expands manufacturing capacity [8] Risk Profiles - Abbott trades at a P/E ratio of 15.71 with a 1.88% dividend yield, reflecting a mature business model [9] - Lilly, with a P/E ratio of 49.5, indicates high growth expectations tied to its GLP-1 dominance, but this also implies higher concentration risk [9]

China has approved 19 innovative medicines — including major treatments from Eli Lilly, Pfizer, and Johnson & Johnson — for its first commercial health insurance drug catalog, creating a new pathway for companies to sell advanced therapies at better prices.The announcement was made Sunday in Guangzhou, marking a major shift in how China plans to support costly drugs that are too expensive for its state insurance program.The new list includes medicines for cancer, Alzheimer's disease, and rare genetic condit ...

Core Viewpoint - The announcement by China's National Healthcare Security Administration on December 7 includes the new basic medical insurance drug catalog and the first version of the commercial insurance innovative drug catalog, highlighting the inclusion of Eli Lilly's Alzheimer's disease modification therapy, Donanemab, in the commercial insurance innovative drug catalog [1] Group 1 - The new drug catalog fills three significant gaps in traditional treatments for Alzheimer's disease: the absence of targeted Aβ plaque drugs, the lack of disease-modifying therapies for Alzheimer's, and the unavailability of drugs targeting mild cognitive impairment due to Alzheimer's [1]